evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

137 questions · 137 findings · 8 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 46 · 33.6%GRADE not reported 3 · 2.2%Very low 21 · 15.3%Low 40 · 29.2%Moderate 21 · 15.3%High 6 · 4.4%

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).

1 finding from 1 review

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).

1 finding from 1 review

LAMA vs placebo

Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis

LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).

1 finding from 1 review

LAMA vs placebo

Pulmonary exacerbations · adults and children with cystic fibrosis

LAMAs showed no clear difference in pulmonary exacerbations: participants reporting ≥1 pulmonary… compared with placebo (moderate certainty).

1 finding from 1 review